What one share of Definium Therapeutics holds
We are a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders. Our mission is to forge a new era of psychiatry by applying scientific rigor to psychedelics, with the goal of developing accessible treatments that unlock healing at scale.
Definium Therapeutics’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | −$3.47 |
|---|---|
| Cash and investments | $4.88 |
| Debt | $0.27 |
| Book value | $6.84 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2020 | — | −$1.91 | — | — | — | $4.27 |
| 2021 | — | −$3.40 | — | — | — | $5.39 |
| 2022 | — | −$1.84 | — | — | — | $3.97 |
| 2023 | — | −$2.44 | — | — | — | $1.90 |
| 2024 | — | −$1.54 | — | — | — | $3.21 |
| 2025 | — | −$2.06 | — | — | — | $3.36 |
Common questions about Definium Therapeutics
How much does one share of Definium Therapeutics earn?
Over the last 12 months, Definium Therapeutics lost $3.47 for each share.
Does Definium Therapeutics pay a dividend?
Definium Therapeutics didn’t pay a dividend over the last 12 months, according to its SEC filings.
What is Definium Therapeutics’s book value per share?
Definium Therapeutics’s book value is $6.84 per share: what would be left for each share if it sold everything at the values on its books and paid every debt, as of June 30, 2026.
How much cash and debt does each share of Definium Therapeutics have?
Each share of Definium Therapeutics has $4.88 of cash and investments and $0.27 of debt, as of June 30, 2026.
Has Definium Therapeutics bought back shares?
Definium Therapeutics’s share count rose about 403% from 2020 to 2025. That dilution means each share owns a smaller slice of the company.
From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.